Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Authors' conclusion
Higher levels of osteoprotegerin and osteopontin are associated with an increased risk of CV events in people with T2D, supporting the hypothesis that pathways involved in bone metabolism play a role in CV disease.
Study context
- Population
- Participants with T2D in the EXSCEL trial of once-weekly exenatide
- Participants
- 5,473 participants
- Comparison
- Bone metabolism biomarkers, per 1 SD increase
- Primary endpoint
- MACE: first occurrence of CV death, nonfatal MI or nonfatal stroke
Methodological detailsproteomic profiling (SomaScan assay) at baseline and 12 months
- Proteomic profiling (SomaScan assay) at baseline and 12 months
Primary result
As reported in the abstract
MACE
MACE occurred
813 participants
14.9%
Osteoprotegerin, HR per 1 SD increase
1.11
95% CI 1.03–1.20P = 0.0047
Osteopontin, HR per 1 SD increase
1.10
95% CI 1.02–1.18P = 0.0095
Further findings
Incremental value of osteoprotegerin and osteopontin added to clinical model for MACE prediction
- C-index (likelihood ratio test P < 0.001); minimal incremental value
- 0.629 vs. 0.638
Osteocalcin and all-cause death and cardiovascular (CV) death
- Osteocalcin had a nonlinear association with all-cause death and with CV death
Original publication
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care. Published 22 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →